Loading
Elucid
Elucid Bioimaging Inc., based in Boston, Massachusetts, is a medical technology company founded in 2013 by Andrew Buckler and Marc Manley. The company focuses on developing AI and machine learning-driven software for the non-invasive diagnosis and treatment of cardiovascular disease. Elucid's mission is to enhance patient care in cardiology by applying precision medicine standards similar to those in oncology. The flagship product, ElucidVivo, features PlaqueIQ™ Technology, which is FDA-cleared and CE-marked. This software analyzes CT angiography images to provide insights into arterial plaque characteristics, assess the risk of plaque rupture, and guide treatment decisions. ElucidVivo supports healthcare professionals, including cardiologists and radiologists, by offering advanced diagnostic tools and predictive analytics for stroke risk. The company has raised over $80 million in funding and continues to expand its technological capabilities in the HealthTech sector.
Funding
Every round, secondary, debt facility or acquisition involving Elucid that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$63M